Draft Approaches for Addressing Training and Experience Requirements for Radiopharmaceuticals Requiring a Written Directive
| Published date | 23 May 2019 |
| Record Number | 2019-10760 |
| Section | Notices |
| Court | Nuclear Regulatory Commission |
Federal Register, Volume 84 Issue 100 (Thursday, May 23, 2019)
[Federal Register Volume 84, Number 100 (Thursday, May 23, 2019)]
[Notices]
[Pages 23812-23813]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-10760]
=======================================================================
-----------------------------------------------------------------------
NUCLEAR REGULATORY COMMISSION
[NRC-2018-0230]
Draft Approaches for Addressing Training and Experience
Requirements for Radiopharmaceuticals Requiring a Written Directive
AGENCY: Nuclear Regulatory Commission.
ACTION: Request for comment; extension of comment period.
-----------------------------------------------------------------------
SUMMARY: On May 2, 2019, the U.S. Nuclear Regulatory Commission (NRC)
requested comments on draft approaches regarding the training and
experience (T&E) requirements for radiopharmaceuticals requiring a
written directive. The public comment period was originally scheduled
to close on June 3, 2019. The NRC is extending the comment period to
July 3, 2019, to allow more time for stakeholders and members of the
public to submit their comments.
DATES: The due date of comments requested in the notice published on
May 2, 2019 (84 FR 18874) is extended. Comments should be submitted no
later than July 3, 2019. Comments received after this date will be
considered if it is practical to do so, but the NRC is only able to
ensure consideration for comments received on or before this date.
ADDRESSES: You may submit comments by any of the following methods:
Federal Rulemaking Website: Go to http://www.regulations.gov and search for Docket ID NRC-2018-0230. Address
questions about NRC docket IDs in regulations.gov to Jennifer Borges;
telephone: 301-287-9127; email: [email protected]. For technical
questions, contact the individual listed in the FOR FURTHER INFORMATION
CONTACT section of this document.
Mail comments to: Office of Administration, Mail Stop:
TWFN-7-A60M, U.S. Nuclear Regulatory Commission, Washington, DC 20555-
0001, ATTN: Program Management, Announcements and Editing Staff.
For additional direction on obtaining information and submitting
comments, see ``Obtaining Information and Submitting Comments'' in the
SUPPLEMENTARY INFORMATION section of this document.
FOR FURTHER INFORMATION CONTACT: Sarah Lopas, Office of Nuclear
Material Safety and Safeguards, U.S. Nuclear Regulatory Commission,
Washington, DC 20555-0001; telephone: 301-415-6360, email:
[email protected].
SUPPLEMENTARY INFORMATION:
I. Obtaining Information and Submitting Comments
A. Obtaining Information
Please refer to Docket ID NRC-2018-0230 when contacting the NRC
about the availability of information for this action. You may obtain
publicly-available information related to this action by any of the
following methods:
Federal Rulemaking Website: Go to http://www.regulations.gov and search for Docket ID NRC-2018-0230.
NRC's Agencywide Documents Access and Management System
(ADAMS): You may obtain publicly-available documents online in the
ADAMS Public Documents collection at http://www.nrc.gov/reading-rm/adams.html. To begin the search, select ``Begin Web-based ADAMS
Search.'' For problems with ADAMS, please contact the NRC's Public
Document Room (PDR) reference staff at 1-800-397-4209, 301-415-4737, or
by email to [email protected]. The ADAMS accession number for each
document referenced is provided the first time that it is mentioned in
the SUPPLEMENTARY INFORMATION section.
NRC's PDR: You may examine and purchase copies of public
documents at the NRC's PDR, Room O1-F21, One White Flint North, 11555
Rockville Pike, Rockville, Maryland 20852.
B. Submitting Comments
Please include Docket ID NRC-2018-0230 in your comment submission.
The
[[Page 23813]]
NRC cautions you not to include identifying or contact information in
comment submissions that you do not want to be publicly disclosed in
your comment submission. All comment submissions are posted at http://www.regulations.gov and entered into ADAMS. Comment submissions are not
routinely edited to remove identifying or contact information.
If you are requesting or aggregating comments from other persons
for submission to the NRC, then you should inform those persons not to
include identifying or contact information that they do not want to be
publicly disclosed in their comment submission. Your request should
state that the NRC does not routinely edit comment submissions to
remove such information before making the comment submissions available
to the public or entering the comment into ADAMS.
II. Discussion
On May 2, 2019, the NRC published a notice in the Federal Register
(84 FR 18874) requesting comments on draft approaches the staff
developed regarding the T&E requirements for radiopharmaceuticals
requiring a written directive. The public comment period was originally
scheduled to close on June 3, 2019. By letter dated May 13, 2019 (ADAMS
Accession No. ML19136A236), the American College of Radiology, the
American Society for Radiation Oncology, and the Society of Nuclear
Medicine and Molecular Imaging jointly requested a 30-day extension to
the public comment period. United Pharmacy Partners, Inc. also
submitted a request for extension by letter dated May 14, 2019 (ADAMS
Accession No. ML19136A238). Additional requests for an extension to the
public comment period were also heard during a May 14, 2019, public
comment meeting. The NRC is granting this request and will extend the
public comment period until July 3, 2019, to allow more time for
medical and regulatory stakeholders and members of the public to submit
their comments.
Dated at Rockville, Maryland, this 17th day of May 2019.
For the Nuclear Regulatory Commission.
Andrea L. Kock,
Director, Division of Materials Safety, Security, State, and Tribal
Programs, Office of Nuclear Material Safety and Safeguards.
[FR Doc. 2019-10760 Filed 5-22-19; 8:45 am]
BILLING CODE 7590-01-P
